Literature DB >> 25085611

Acidosis: progression of chronic kidney disease and quality of life.

Ione de-Brito Ashurst1, Emma O'Lone, Tarun Kaushik, Kieran McCafferty, Muhammad M Yaqoob.   

Abstract

Metabolic acidosis (MA) is relatively common in patients with chronic kidney disease (CKD) particularly in stages 4 and 5. It is assumed to play a contributory role in the development of several complications including bone disease, skeletal muscle wasting, altered protein synthesis, and degradation. Recent evidence also suggests that even mild acidosis might play a role in progressive glomerular filtration rate loss. Experimental and clinical studies suggest that correction of acidosis by alkali therapy attenuates these complications and improves quality of life. Despite several recent small and single-center studies supporting this notion, more robust evidence is required with regard to the long-term benefits of alkali therapy, type of alkali supplements, and the optimal level of serum bicarbonate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085611     DOI: 10.1007/s00467-014-2873-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

Review 1.  Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment.

Authors:  Jeffrey A Kraut; Ira Kurtz
Journal:  Am J Kidney Dis       Date:  2005-06       Impact factor: 8.860

Review 2.  Ammonium excretion in chronic metabolic acidosis: benefits and risks.

Authors:  M L Halperin; J H Ethier; K S Kamel
Journal:  Am J Kidney Dis       Date:  1989-10       Impact factor: 8.860

3.  Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease.

Authors:  A Jara; A J Felsenfeld; J Bover; C R Kleeman
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

4.  Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease.

Authors:  V E Torres; B D Cowley; M G Branden; I Yoshida; V H Gattone
Journal:  Exp Nephrol       Date:  2001

5.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

6.  Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis.

Authors:  E McSherry; R C Morris
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

7.  Effects of oral sodium bicarbonate in patients with CKD.

Authors:  Matthew K Abramowitz; Michal L Melamed; Carolyn Bauer; Amanda C Raff; Thomas H Hostetter
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 8.237

8.  Correction of acidosis in CAPD decreases whole body protein degradation.

Authors:  K A Graham; D Reaich; S M Channon; S Downie; E Gilmour; J Passlick-Deetjen; T H Goodship
Journal:  Kidney Int       Date:  1996-05       Impact factor: 10.612

9.  The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway.

Authors:  J L Bailey; X Wang; B K England; S R Price; X Ding; W E Mitch
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

10.  Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. Part II--Kidney hypertrophy and calcium deposition.

Authors:  Aquiles Jara; Cecilia Chacón; Magdalena Ibaceta; Andres Valdivieso; Arnold J Felsenfeld
Journal:  Nephrol Dial Transplant       Date:  2004-05-25       Impact factor: 5.992

View more
  7 in total

1.  Impact of Metabolic Acidosis and Alkali Therapy on Linear Growth in Children with Chronic Kidney Disease: What Is the Current Evidence?

Authors:  Emma H Ulrich; Rahul Chanchlani
Journal:  Kidney360       Date:  2022-03-09

2.  Renal aspects of metabolic acid-base disorders in neonates.

Authors:  Silvia Iacobelli; Jean-Pierre Guignard
Journal:  Pediatr Nephrol       Date:  2018-11-19       Impact factor: 3.714

3.  Rationale and Design of a Randomized Placebo-Controlled Clinical Trial Assessing the Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease.

Authors:  Martin Gritter; Liffert Vogt; Stanley M H Yeung; Rosa D Wouda; Christian R B Ramakers; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn
Journal:  Nephron       Date:  2018-06-29       Impact factor: 2.847

4.  High (≥6.5) Spontaneous and Persistent Urinary pH Is Protective of Renal Function at Baseline and during Disease Course in Idiopathic Membranous Nephropathy.

Authors:  Claudio Bazzi; Elena Tagliabue; Sara Raimondi; Virginia Rizza; Daniela Casellato; Masaomi Nangaku
Journal:  Int J Nephrol       Date:  2015-07-30

5.  The Effect of Intraoperative Alkali Treatment on Recovery from Atracurium-Induced Neuromuscular Blockade in Renal Transplantation: A Randomized Trial.

Authors:  Navid Noraee; Mohammad Fathi; Majid Golestani Eraghi; Ali Dabbagh; Nilofar Massoudi
Journal:  Anesth Pain Med       Date:  2017-01-01

6.  Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.

Authors:  Daisy Liu; Ana Catalina Alvarez-Elías; Brooke Wile; Vladimir Belostotsky; Guido Filler
Journal:  BMC Nephrol       Date:  2017-06-28       Impact factor: 2.388

7.  Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol.

Authors:  Anna Wiegand; Alexander Ritter; Nicole Graf; Spyridon Arampatzis; Daniel Sidler; Karine Hadaya; Thomas F Müller; Carsten A Wagner; Rudolf P Wüthrich; Nilufar Mohebbi
Journal:  BMC Nephrol       Date:  2018-07-13       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.